In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hang Onto The Launch: Investor Outlook Is Brighter For Some Biotechs

Executive Summary

Successful biotech launches like Regeneron’s Eylea, Vertex’s Incivek and others have investors reconsidering the “short the launch” mentality that pervaded the industry a year ago, though no one is throwing caution to the wind.


Related Content

A Banner Year For Pharma: M&A Tops 2009 Merger Mania
Onyx’s Transformative Year: From Productive Partner To Big Cap Contender?
Renewed Confidence In Data, Launches Drive J.P. Morgan Stocks
Jakafi Launch Going Smoothly, But Incyte Confuses Investors
Regeneron Plays It Safe With Eylea, Aims To Undercut Lucentis
Disappointing Provenge Sales Stir Doubts About Demand


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts